Miron Talia, Rabinkov Aharon, Peleg Edna, Rosenthal Talma, Mirelman David, Wilchek Meir
Weizmann Institute of Science, Chaim Sheba Medical Center, Tel Hashomer, Israel.
Am J Hypertens. 2004 Jan;17(1):71-3. doi: 10.1016/s0895-7061(03)01035-5.
Allylmercaptocaptopril (CPSSA) was synthesized by reacting captopril with pure allicin. Fructose-induced hypertensive groups of rats were fed a fructose-rich diet for 3 weeks, and then received the diet plus either CPSSA (40 to 56 mg or 138 to 194 micromol/L/kg/d) or captopril (80 mg or 369 micromol/L/kg/d) for 2 more weeks. CPSSA (both doses) significantly lowered blood pressure (BP) from 153.4 to 120.8 mm Hg (P <.005). Captopril gave similar results, lowering BP from 150.7 to 123 mm Hg (P <.005). CPSSA also decreased the high levels of triglycerides to normal. The new stable compound allylmercaptocaptopril combines the beneficial properties of captopril and allicin and is a potential candidate for antihypertensive drug therapy.
烯丙基巯基卡托普利(CPSSA)通过卡托普利与纯大蒜素反应合成。果糖诱导的高血压大鼠组喂食富含果糖的饮食3周,然后在接下来的2周内接受该饮食并添加CPSSA(40至56毫克或138至194微摩尔/升/千克/天)或卡托普利(80毫克或369微摩尔/升/千克/天)。CPSSA(两种剂量)均显著降低血压(BP),从153.4降至120.8毫米汞柱(P<.005)。卡托普利也有类似结果,将血压从150.7降至123毫米汞柱(P<.005)。CPSSA还将高水平的甘油三酯降至正常。新的稳定化合物烯丙基巯基卡托普利兼具卡托普利和大蒜素的有益特性,是抗高血压药物治疗的潜在候选药物。